Dr. Timothy D. Moore
Claim this profileThe Mark H Zangmeister Center
Expert in Lung Cancer
Expert in Breast Cancer
126 reported clinical trials
208 drugs studied
About Timothy D. Moore
Education:
- Earned a Medical degree (MD) from the University of Pittsburgh School of Medicine.
- Completed an Internship at the University of Cincinnati School of Medicine.
- Served as Chief Resident during his Residency at Mercy Hospital in Pittsburgh.
- Undertook a Fellowship in Hematology/Oncology at The Ohio State University School of Medicine.
Experience:
- Held Senior Investigator positions at the National Cancer Institute, focusing on the Cancer Therapy Evaluation Program.
- Served as an Attending physician at NCI-Navy Medical Oncology Services, Bethesda National Naval Hospital.
- Co-Medical Director for Palliative Care at The Zangmeister Cancer Center.
- Board certified in General Internal Medicine, Hematology, Medical Oncology, and Hospice & Palliative Care Medicine.
Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Timothy D. Moore is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Financial Navigation
for Cancer Patients
This clinical trial evaluates the effect of Cost Communication and Financial Navigation (CostCOM) intervention on adherence to care and financial burden in cancer patients. Many cancer patients experience financial hardship due to high medical out of pocket costs (OOPC), changes in employment, income and insurance. Financial hardship can lead to a delay or a stop in cancer care, and is linked to poor quality of life. Financial navigation programs, such as CostCOM, provide financial counseling, education and connections to appropriate resources to reduce financial barriers to healthcare and minimize financial stress and burden. CostCOM may improve adherence to care and decrease financial burden in patients with cancer.
Recruiting1 award N/A
More about Timothy D. Moore
Clinical Trial Related6 years of experience running clinical trials · Led 126 trials as a Principal Investigator · 42 Active Clinical TrialsTreatments Timothy D. Moore has experience with
- Carboplatin
- Paclitaxel
- Pembrolizumab
- Nivolumab
- Cisplatin
- Atezolizumab
Breakdown of trials Timothy D. Moore has run
Lung Cancer
Breast Cancer
Cancer
Breast cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Timothy D. Moore specialize in?
Timothy D. Moore focuses on Lung Cancer and Breast Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Timothy D. Moore currently recruiting for clinical trials?
Yes, Timothy D. Moore is currently recruiting for 42 clinical trials in Columbus Ohio. If you're interested in participating, you should apply.
Are there any treatments that Timothy D. Moore has studied deeply?
Yes, Timothy D. Moore has studied treatments such as Carboplatin, Paclitaxel, Pembrolizumab.
What is the best way to schedule an appointment with Timothy D. Moore?
Apply for one of the trials that Timothy D. Moore is conducting.
What is the office address of Timothy D. Moore?
The office of Timothy D. Moore is located at: The Mark H Zangmeister Center, Columbus, Ohio 43219 United States. This is the address for their practice at the The Mark H Zangmeister Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.